Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CDH3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDH3 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. HEK293 expressed for native glycosylation. Sequence Verified. |
View CDH3 Products |
| Gene Delivery | CDH3 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based binding assays. |
View CDH3 Products |
| Benchmark Ab | Anti-CDH3 Recombinant Antibody Biosimilar sequence based on clinical-stage benchmark antibodies (e.g., DS-3939 analog) for positive control. |
View CDH3 Products |
| Validator | CDH3 siRNA Set Target-specific knockdown pool for specificity and functional assay validation. |
View CDH3 Products |
| Related Target A | CDH1 (E-cadherin) Essential counter-screening target. High homology with CDH3; cross-reactivity must be ruled out to prevent systemic toxicity. |
View CDH1 Products |
| Related Target B | CDH2 (N-cadherin) Homologue used for selectivity profiling to ensure cadherin subtype specificity in solid tumor targeting. |
View CDH2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cadherin subfamily cross-reactivity (CDH1/CDH2 off-target binding) | Highly purified CDH1 and CDH2 proteins available for stringent counter-screening panels. |
| Conformation-sensitive antibody screening | Lentiviral vectors for stable CDH3 cell-line generation, preserving native membrane conformation. |
| Lack of standardized positive controls | Sequence-verified clinical benchmark biosimilars for assay calibration. |
| Target validation false positives | Sequence-verified siRNA knockdown validation tools to confirm target-specific phenotypic effects. |
Live CDH3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CDH3 (P-cadherin) therapeutics is intensifying, with major players shifting focus from traditional mAbs to next-generation Antibody-Drug Conjugates (ADCs) and bispecific constructs. Overexpressed in multiple solid tumors—including triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), ovarian, and pancreatic cancers—while showing restricted expression in normal tissues, CDH3 serves as an ideal tumor-associated antigen (TAA). As first-generation therapies reach the clinic, the next wave of R&D is targeting highly selective epitopes that minimize cross-reactivity with E-cadherin (CDH1) to optimize the therapeutic index.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Antibody-Drug Conjugate) | Daiichi Sankyo (DS-3939), Pfizer/Seagen (SGN-CDH3A) | Solid Tumors, TNBC, Lung Cancer | Internalization Assay & High-purity ECD-Fc for affinity profiling |
| Bispecific / Multi-specific | Academic Institutes, Biotech startups | Ovarian & Pancreatic Cancer | Simultaneous binding assays (Need CDH3 and immune cell recruiter antigens) |
| CAR-T / Cell Therapy | Innovative Biotech developers | Advanced Solid Tumors | Cell-surface density and stable cell-line binding assays (Lentivirus-mediated expression) |